Vaishali Sanchorawala, MD
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College

Pronouns: she/her/hers

72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)

Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.

Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Boston University School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.

Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.

Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.

She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.

Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.

Associate Director
Boston University School of Medicine
Amyloidosis Center

Boston University
BU-BMC Cancer Center

Boston Medical Center
Stem Cell Transplantation Program
Hematology & Medical Oncology

International Society of Amyloidosis

Executive committee
Amyloidosis Research Consortium

Associate Editor
Amyloid: The Journal of Protein Folding disorders

A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2021 (PI)
Millennium Pharmaceuticals, Inc.

A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)
Celgene Corporation

Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Co-Investigator)
The Brigham and Women's Hospital, Inc. NIH NHLBI

A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium

Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc

A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2019 (Co-Investigator)
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.

Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.

Showing 10 of 14 results. Show All Results

CAEL-101 301: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/30/2040 (PI)
Caelum Biosciences, Inc.

CAEL-101 302: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/30/2040 (PI)
Caelum Biosciences, Inc.

NEOD001-301: A Phase 3, Randomized, Multicenter, Double-Blin
06/23/2021 - 06/22/2024 (PI)
Prothena Biosciences Limited

STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
12/01/2020 - 11/30/2023 (PI)
Sorrento Therapeutics, Inc.

A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…
04/23/2020 - 04/22/2023 (PI)
Karyopharm Therapeutics Inc.

07/23/2020 - 01/22/2023 (PI)
Weill Cornell Medical College Janssen Scientific A

DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2022 (PI)
Dana Farber Millennium Pharmaceu

Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…
11/21/2019 - 11/20/2022 (PI)
Oncopeptides AB

11/17/2017 - 11/17/2022 (PI)
Janssen Research and Development, LLC

54767414MMY3019 DARA
04/15/2019 - 04/15/2022 (PI)
Janssen Scientific Affairs LLC

Showing 10 of 15 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Wechalekar AD, Sanchorawala V. Daratumumab in amyloidosis. Blood. 2022 May 04. PMID: 35507692
  2. Staron A, Verma K, Sanchorawala V. Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. Br J Haematol. 2022 May 02.View Related Profiles. PMID: 35499208
  3. Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone?±?daratumumab: Results from the ANDROMEDA study. Am J Hematol. 2022 Jun 01; 97(6):719-730. PMID: 35293006
  4. Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Mar 09.View Related Profiles. PMID: 35367193
  5. Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid. 2022 Mar 07; 1-6.View Related Profiles. PMID: 35253562
  6. Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644.View Related Profiles. PMID: 35227897; DOI: 10.1016/j.critrevonc.2022.103644;
  7. Mendelson L, Sanchorawala V, Connors L, Joshi T, Doros G, Pogrebinsky A, Havasi A. Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Med. 2022 Apr; 4(4):100427.View Related Profiles. PMID: 35342879; PMCID: PMC8942830; DOI: 10.1016/j.xkme.2022.100427;
  8. Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. Hemasphere. 2022 Feb; 6(2):e681. PMID: 35106451; PMCID: PMC8797507; DOI: 10.1097/HS9.0000000000000681;
  9. Abdallah M, Sanchorawala V. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. Am J Med. 2022 Apr; 135 Suppl 1:S30-S37.View Related Profiles. PMID: 35081382
  10. Cuddy SAM, Jerosch-Herold M, Falk RH, Kijewski MF, Singh V, Ruberg FL, Sanchorawala V, Landau H, Maurer MS, Yee AJ, Bianchi G, Di Carli MF, Liao R, Kwong RY, Dorbala S. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2022 Apr; 15(4):594-603.View Related Profiles. PMID: 34922860; PMCID: PMC8995332; DOI: 10.1016/j.jcmg.2021.09.032;
Showing 10 of 213 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 213 publications over 25 distinct years, with a maximum of 19 publications in 2020


2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 East Concord Street, K-503
Boston MA 02118
Google Map

Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department